IP Library Granted Patent US 8,206,734
Granted Patent B2
US 8,206,734 · App. 12/873,130 · Granted Jun 26, 2012

Long term drug delivery devices with polyurethane based polymers and their manufacture

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,206,734
App. No.
12/873,130
Granted
Jun 26, 2012
Kind
B2
Abstract

This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. a reservoir, said reservoir comprising; 2. at least one active ingredient; and, optionally, 3. at least one pharmaceutically acceptable carrier; a polyurethane based polymer completely surrounding the reservoir.

Claims (12)

1. A method of delivering one or more active ingredients to a subject, comprising implanting an implantable drug delivery device into the subject, in which the implantable drug delivery device comprises a polyurethane-based polymer configured to provide a cylindrically shaped reservoir and deliver the one or more active ingredients to the subject at a substantially zero order release rate in vitro by diffusion through the polyurethane-based polymer for a period of six weeks or more from the time of implantation, wherein the reservoir is sealed after being charged with an effective amount of a solid formulation comprising one or more active ingredients exhibiting hydrophilic characteristics, and the polyurethane-based polymer exhibits a percent equilibrium water content (% EWC) of about 30% or less.

2. The method of claim 1 in which the % EWC of the polyurethane-based polymer ranges from about 15% to about 30%.

3. The method of claim 1 in which the one or more active ingredients or their pharmaceutically acceptable salts are freely soluble in water.

4. The method of claim 3 in which the one or more active ingredients comprises a peptide.

5. The method of claim 4 in which the one or more active ingredients comprises an LHRH agonist.

6. The method of claim 5 in which the one or more active ingredients comprises histrelin or a pharmaceutically acceptable acid addition salt thereof.

7. An implantable drug delivery device for releasing one or more active ingredients at a substantially zero order rate in vitro by diffusion through a polyurethane-based polymer for a period of six weeks or more from the time of implantation, said implantable drug delivery device comprising a polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of a solid formulation comprising one or more active ingredients exhibiting hydrophilic characteristics and the polyurethane-based polymer exhibits a percent equilibrium water content (% EWC) of about 30% or less.

8. The implantable drug delivery device of claim 7 in which the polyurethane-based polymer exhibits a % EWC ranging from about 15% to about 30%.

9. The implantable drug delivery device of claim 8 in which the solid formulation includes one or more pharmaceutically acceptable carriers that are not required for the substantially zero order release rate in vitro of the one or more active ingredients through the polyurethane-based polymer.

10. The implantable drug delivery device of claim 9 in which the one or more pharmaceutically acceptable carriers are not required for the substantially zero order release rate in vitro of the one or more active ingredients as governed by Fick's Law of Diffusion.

11. The implantable drug delivery device of claim 9 in which the solid formulation includes stearic acid.

12. The method of claim 1 in which the at least one active ingredient is selected from drugs that can act on the central nervous system, psychic energizers, tranquilizers, anti-convulsants, muscle relaxants, anti-parkinson, analgesic, anti-inflammatory, anesthetic, antispasmodic, muscle contractants, anti-microbials, anti-malarials, hormonal agents, sympathomimetic, cardiovascular, diuretics, and antiparasitic.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Feb 3, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 041171/0936 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2017
From: VALERA PHARMACEUTICALS, INC.
To: INDEVUS PHARMACEUTICALS, INC.
Reel/Frame 041123/0514 →
CHANGE OF NAME Recorded Jan 30, 2017
From: VALERA PHARMACEUTICALS, INC.
To: ENDO PHARMACEUTICALS VALERA INC.
Reel/Frame 041564/0401 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2017
From: ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS VALERA INC.
To: BRAEBURN PHARMACEUTICALS, INC.
Reel/Frame 041081/0926 →
CHANGE OF NAME Recorded Oct 27, 2016
From: INDEVUS PHARMACEUTICALS, INC.
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 040151/0432 →
MERGER Recorded Oct 27, 2016
From: VALERA PHARMACEUTICALS, INC.
To: INDEVUS PHARMACEUTICALS, INC.
Reel/Frame 040149/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2016
From: KUO, SHENG-HUNG; KUZMA, PETR
To: VALERA PHARMACEUTICALS, INC.
Reel/Frame 040139/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2016
From: BRAEBURN PHARMACEUTICALS BVBA SPRL
To: BRAEBURN PHARMACEUTICALS, INC.
Reel/Frame 038800/0527 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS INC.
To: BRAEBURN PHARMACEUTICALS BVBA SPRL
Reel/Frame 034206/0253 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS, INC.; ENDO PHARMACEUTICALS, INC.; AMS RESEARCH CORPORATION; AMERICAN MEDICAL SYSTEMS, INC.; LASERSCOPE
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0440 →
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 032380/0226 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 25434/842 Recorded Jul 11, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 026571/0616 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ENDO PHARMACEUTICALS SOLUTIONS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026557/0373 →
SECURITY AGREEMENT Recorded Dec 1, 2010
From: ENDO PHARMACEUTICALS SOLUTIONS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025434/0842 →